Multiple Sclerosis – Emerging Therapies – Zinbryta Launch Tracking Wave 1 (US)

Multiple Sclerosis | Emerging Therapies | Zinbryta | US is a three-wave series that tracks the introduction of Zinbryta for the treatment of multiple sclerosis (MS). The series is based on primary research data collected at one, six, and twelve months post-commercial launch with U.S. neurologists. Along with awareness of, sources of familiarity with, and perceptions related to Zinbryta, the research assesses trial, adoption, and usage, including anticipated future trends, of Zinbryta. We also explore Biogen/AbbVie’s promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched MS agents.

Questions answered:

  • What is the awareness of, familiarity with, and perceptions related to Zinbryta among U.S. neurologists?
  • Among prescribers, for which patients are they prescribing Zinbryta, what are the reasons for prescribing, and how satisfied are they with Zinbryta?
  • What promotional messages and activities are Biogen/AbbVie employing in support of the Zinbryta launch?
  • How do prescribers and nonprescribers compare across key metrics?
  • How is the trial and adoption of Zinbryta tracking compared to other recent product launches in the MS market?

Scope:

Markets covered: United States.

Primary research: 75 neurologists surveyed for Waves 1 and 2, 100 neurologists surveyed for Wave 3; 10 qualitative interviews per wave with a subset of survey respondents.

Indication coverage: Relapsing-remitting MS.

Table of contents

  • Multiple Sclerosis - Emerging Therapies - Zinbryta Launch Tracking Wave 1 (US)
    • Key Findings
      • Benchmarking Zinbryta's Launch Success vs. the Competition
        • One Month Postlaunch, Zinbryta Is on Par with Benchmark DMTs on Most Metrics
        • Benchmarking Zinbryta Launch Success vs. the Competition
      • Prescriber and Nonprescriber Profiles
        • Differences Between Zinbryta Prescribers and Nonprescribers
        • Differences Between Zinbryta Prescriber and Nonprescriber Profiles
      • Zinbryta Awareness and Perceptions
        • Unaided and Aided Awareness of Zinbryta
          • Aided Awareness of Zinbryta Slightly Lags Benchmark DMTs
          • Unaided Awareness of Drugs Approved or Launched for the Treatment of RR-MS
          • Aided Awareness of Zinbryta
        • Familiarity with Zinbryta
          • Most Respondents Report Moderate Familiarity with Zinbryta
          • Level of Familiarity with Zinbryta
          • Aided Awareness of Zinbryta's Indication
          • Aided Awareness of the General Line of Therapy Recommendation for Zinbryta
          • Aided Awareness of Zinbryta's Dosing Interval
        • Sources of Familiarity with Zinbryta
          • Colleagues and Academic Publications Are Key Sources of Familiarity with Zinbryta
        • Initial Reaction to and Interest in Zinbryta
          • Surveyed Neurologists' Initial Reaction to Zinbryta is More Favorable Than Several Benchmark DMTs
          • Zinbryta Product Profile
          • Zinbryta Information Requiring Additional Education
          • Initial Reaction to Zinbryta
          • Level of Interest in Learning More About Zinbryta
        • Impressions of Zinbryta
          • Most Respondents' Consider Zinbryta's Risk-Benefit Profile to Be Balanced
          • Unaided Advantages of Zinbryta
          • Unaided Disadvantages of Zinbryta
          • Rating of Zinbryta's Risk-Benefit Balance
          • Statement Agreements Regarding Zinbryta's Clinical Profile
          • Physician Quotes on Impressions of Zinbryta
        • Prescriber and Nonprescriber Profiles
          • Early Zinbryta Adopters Appear More Specialized and Risk Tolerant in Managing MS
          • Differences Between Zinbryta Prescriber and Nonprescriber Profiles
      • Zinbryta Trial and Use
        • Willingness to Prescribe Zinbryta
          • Respondents Generally Signal Willingness to Prescribe Zinbryta
          • Willingness to Prescribe Zinbryta to MS Patients
          • Impact of Clinical and Nonclinical Attributes on Willingness to Prescribe Zinbryta
          • Enrollment in the Zinbryta REMS
          • Ease of Enrollment in the Zinbryta REMS
          • Physician Quotes on Willingness to Prescribe Zinbryta
        • Number of Patients Currently Receiving Zinbryta
          • Most Current Zinbryta Patients Were Switched from an Injectable or Infusible DMT
          • Zinbryta Prescriber Base
          • Average Zinbryta Patient Volume
          • Zinbryta Discontinuation Rate
          • Reasons for Discontinuation of Zinbryta
          • Source of Business for Current Zinbryta Patients
          • Source Therapy for Current Patients Who Were Switched to Zinbryta
          • Number of Prior DMTs for Patients Switched to Zinbryta
          • Current Zinbryta Prescribing by Disease Classification
          • Reasons for Starting/Switching to Zinbryta
          • Zinbryta Follow-Up Visits
          • Zinbryta Treatment Response
          • Percentage of Patients Ever Treated With Zinbryta Experiencing Select AEs
          • Top Three Obstacles to Prescribing Zinbryta More Frequently
          • Physician Quotes on Current Use of Zinbryta
          • Percentage of Neurologists Receiving a Patient Request for Zinbryta
          • Mean Number of Patients Requesting Zinbryta
          • Action Based on Specific Zinbryta Patient Requests
        • Reasons for Not Yet Prescribing Zinbryta
          • Lack of Zinbryta Familiarity and Potential Safety Risks Keep Some Neurologists on the Sidelines
          • Reasons for Never Prescribing Zinbryta
        • Anticipated Zinbryta Use
          • Respondents Expect Zinbryta to Gain Share While Platform Injectables Decline
          • Anticipated Timing for Zinbryta Prescribing Among Current Nonprescribers
          • Percentage of MS Patients Who Are Zinbryta Candidates, by Disease Classification
          • Percentage of MS Patients Who Are Zinbryta Candidates, by Treatment Situation
          • Physician Quotes on Anticipated Zinbryta Use
          • Current and Anticipated DMT Treatment Rate
          • Current and Anticipated Brand Allocation Among DMT-Treated RR-MS Patients
        • Zinbryta Performance on Key Attributes
          • Prescribers Reported High Overall Satisfaction with Zinbryta
          • Overall Satisfaction with Zinbryta Among Prescribers
          • Rating of Zinbryta's Performance on Clinical and Nonclinical Attributes
      • Effectiveness of Face-to-Face Detailing for Zinbryta
        • Zinbryta Sales Representative Frequency and Reach
          • Sales Representative Detailing Reach
          • Detailing Visits by Marketing Company
        • Satisfaction with Zinbryta Sales Representative
          • Satisfaction with Zinbryta Sales Representatives
        • Zinbryta Message Recall
          • Early Zinbryta Messaging Includes Zinbryta's Indication and Drug Initiation Logistics
          • Unaided Zinbryta Message Recall During Recent Detail
          • Aided Zinbryta Message Recall During Recent Detail
          • Physician Quotes on Zinbryta Message Recall

    launch Related Market Assessment Reports